Our Science
XTRemisBio, Inc. is a preclinical stage company focused on difficult-to-treat cancers. Lead candidate XP-524 is a first-in-class, oral, small molecule “KRAS eraser” that has extended survival in preclinical models of pancreatic cancer, as well as synergy with immunotherapies and efficacy in cells resistant to commercially available RAS inhibitors.